Study of a new drug plus standard chemo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if adding the experimental drug pelareorep to standard chemotherapy (FOLFIRI) and bevacizumab can help people with a specific type of advanced colorectal cancer that has a RAS mutation and is not caused by high microsatellite instability. You may be able to join if you've already tried one type of chemotherapy and it stopped working or you couldn't tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is advanced and cannot be removed with surgery.
- You have a RAS mutation and your tumor is not MSI-high (a type of genetic instability).
- You have already tried a first-line chemotherapy that included oxaliplatin, and it either didn't work or you couldn't continue it.
- You are healthy enough to get standard chemotherapy (FOLFIRI with bevacizumab).
- You have not had irinotecan (a drug in FOLFIRI) before.
- You do not have active autoimmune disease or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This study is testing a combination of drugs for colorectal cancer that has spread and hasn't responded to first-line treatment. It aims to see if these drugs can help control the cancer and improve outcomes for people in your situation.
This study tests a new experimental drug (PF-08634404) combined with standard chemotherapy for people with stage 4 colorectal cancer who have not yet been treated for their advanced disease. The goal is to see if the combination helps shrink or slow the growth of tumors.
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
Hear when a new mCRC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.